On October 1, 2024, Blake Borgeson, Director at Recursion Pharmaceuticals Inc (RXRX, Financial), sold 11,447 shares of the company. The transaction was executed at a price of $6.22 per share, as detailed in the SEC Filing. Following this transaction, the insider now owns 7,098,428 shares of Recursion Pharmaceuticals Inc.
Recursion Pharmaceuticals Inc is a biotechnology firm that utilizes an AI-driven platform to decode biology and radically improve lives. The company's approach integrates automated experiments with computational biology to discover new drugs and identify novel uses for existing drugs.
Over the past year, the insider has sold a total of 359,070 shares and has not made any purchases. The broader trend within the company shows a pattern of insider selling, with 69 insider sales and no insider buys over the last year.
Shares of Recursion Pharmaceuticals Inc were trading at $6.22 on the day of the transaction, giving the company a market cap of approximately $1.71 billion. According to the GF Value, the stock has a price-to-GF-Value ratio of 0.48, suggesting that it is a Possible Value Trap, Think Twice before investing.
The GF Value is calculated based on historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, along with a GuruFocus adjustment factor based on past returns and growth, and future business performance estimates from Morningstar analysts.
This insider sale could be of interest to current and potential investors, providing insight into the insider's perspective on the stock's valuation and future prospects.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
